Comparative Pharmacology
Head-to-head clinical analysis: SILDENAFIL CITRATE versus STAXYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SILDENAFIL CITRATE versus STAXYN.
SILDENAFIL CITRATE vs STAXYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sildenafil citrate inhibits phosphodiesterase type 5 (PDE5) in the corpus cavernosum, increasing cGMP levels and enhancing nitric oxide-mediated smooth muscle relaxation, leading to penile erection. It also inhibits PDE5 in pulmonary vasculature, causing vasodilation and reducing pulmonary artery pressure.
Selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). By inhibiting PDE5, sildenafil increases intracellular cGMP levels in the corpus cavernosum, enhancing the relaxant effect of nitric oxide (NO) on smooth muscle cells, thereby facilitating penile erection in response to sexual stimulation.
50 mg orally as needed approximately 1 hour before sexual activity; range 25-100 mg based on efficacy and tolerability; maximum dosing frequency once per day.
10 mg sublingually as needed, 30–60 minutes before sexual activity. Maximum 1 dose per 24 hours.
None Documented
None Documented
Terminal elimination half-life 3-5 hours; clinical effect duration shorter due to distribution.
Terminal elimination half-life is approximately 4-5 hours; clinically, no accumulation with once-daily dosing
Approximately 80% fecal, 13% renal as metabolites; <1% unchanged in urine.
Renal (approximately 90% as metabolites, <2% unchanged); fecal (10%)
Category A/B
Category C
PDE5 Inhibitor
PDE5 Inhibitor